These potential barriers to effective care of people with T2D on insulin therapy each indicate an objective concern that helps to frame the possible solutions and 74.3% of survey participants agreed that additional resources will be needed to support primary care teams managing individuals with T2D on insulin using CGM (Table 4). The gene discussed is INS; the disease is type 2 diabetes mellitus.